Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

1.3%

1 terminated out of 77 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

4%

3 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed with results

Key Signals

1 with results80% success

Data Visualizations

Phase Distribution

54Total
Not Applicable (9)
Early P 1 (11)
P 1 (25)
P 2 (6)
P 3 (1)
P 4 (2)

Trial Status

Recruiting49
Not Yet Recruiting17
Completed4
Enrolling By Invitation3
Suspended1
Terminated1

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (77)

Showing 20 of 20 trials
NCT07641634Phase 1Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis

NCT07642297Not Yet RecruitingPrimary

TL1A Inhibition in Systemic Sclerosis-Related Skin Fibrosis and Immunological Alterations: A Proof-of-Concept In Vitro Study (FIBROSTOP)

NCT06708845Phase 1Recruiting

US Zamto-cel Autoimmune Diseases

NCT05000216Phase 2Terminated

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT07527936Early Phase 1SuspendedPrimary

A Study of BEN301 Injection in theTreatment of Autoimmune Diseases

NCT06991114Phase 2Recruiting

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT06308978Phase 1Recruiting

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

NCT07586267Early Phase 1Recruiting

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

NCT07473154Phase 1Recruiting

Controlling Hyperactive Immunity With Long-lived Lymphocytes

NCT07085676Phase 1RecruitingPrimary

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

NCT06672822Phase 2RecruitingPrimary

Intralesional Injection of STS in Treatment of Calcinosis

NCT06655155Phase 2RecruitingPrimary

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

NCT07544225Phase 1Not Yet Recruiting

Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases

NCT07535931Phase 1Not Yet RecruitingPrimary

Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Systemic Sclerosis

NCT07526350Early Phase 1Recruiting

MTS109 in Patients With Refractory Autoimmune Diseases

NCT07087912Phase 4Recruiting

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

NCT07523282Phase 1Not Yet Recruiting

Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases

NCT07507201Early Phase 1Recruiting

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

NCT07402226Not ApplicableRecruitingPrimary

Systemic Sclerosis DIet for GastrointESTinal Symptoms

NCT06658483Enrolling By InvitationPrimary

Hand ScleroDerma Lived Experience Scale in Individuals With Systemic Sclerosis

Scroll to load more

Research Network

Activity Timeline